Scientists probe shared immune flaw in COVID-19 and blood cancers
NCT ID NCT04953312
Summary
This study aimed to understand how severe COVID-19 disrupts the body's production of immune cells, similar to what happens in certain blood cancers. Researchers planned to compare blood cell samples from three groups: severe COVID-19 patients, people with chronic blood cancers, and healthy individuals. The goal was to learn how a specific protein called calprotectin might drive this harmful process, hoping to identify future treatment targets. (Note: This study was withdrawn before enrolling participants.)
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Gustave Roussy Institut
Villejuif, 94800, France
Conditions
Explore the condition pages connected to this study.